CTMX
CytomX Therapeutics, Inc.
$3.76
-0.20 (-4.93%)
At close · Jul 10
Market Cap
$818.56M
Shares
217,702,919
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.76
Open$4.00
Day$3.62–4.02
52W$1.72–8.21
Avg vol 30d4.5M
Short int35.6M · 16.3% float · 4.3d
Short vol49%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 4, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
+6%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
31%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+29%
trailing
6-month return
−12%
trailing
YTD return
−12%
this year
Relative strength
−21%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
2 of 180 funds reported for Jun 30 · net +39.4K sh shares · +1 new
Insider flow
Distributing
Net -$5.0K over 90 days · 100% sells
Short interest
Rising
16.34% of float · ▲ +16.2% MoM · 4.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
180 holders — near 3-yr high, broad support
Squeeze score
79
high risk · 0–100
Fundamentals
Revenue growth
−45%
Y/Y
Free cash flow
$-75.8M
Balance sheet
$9.7M
net cash
Quant / Vol
risk profile
Volatility
94%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
+6%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
31%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
2 of 180 funds reported for Jun 30 · net +39.4K sh shares · +1 new
Insider flow
Distributing
Net -$5.0K over 90 days · 100% sells
Short interest
Rising
16.34% of float · ▲ +16.2% MoM · 4.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
180 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $4 · 31%
52-wk high $8
vs 200-day avg -10%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTMX
this stock
CytomX Therapeutics, Inc.
|
$818.56M | -11.7% | -44.8% | — | 16.3% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTMX | -1.6% | +29.2% | -11.5% | +0.3% | -11.7% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -2.9% | +25.1% | -20.6% | -0.8% | -22.5% |